Wogonin Mitigates Depression by Inhibiting TNF-α/TNFR1/CXCL1 Signalling-Mediated Astrocyte Activation - PubMed
6 hours ago
- #Depression
- #Neuroinflammation
- #Astrocyte Activation
- Wogonin shows antidepressant effects by reducing neuroinflammation and astrocyte activation.
- It works by inhibiting the TNF-α/TNFR1/CXCL1 signaling pathway in both in vitro and in vivo studies.
- In vitro, wogonin lessens LPS-induced astrocyte activation and decreases TNF-α and CXCL1 protein levels.
- Adding recombinant TNF-α (r-TNF-α) reverses wogonin's inhibitory effects on this pathway.
- In a CUMS mouse model, wogonin alleviates depression-like behaviors and restores hippocampal synaptic plasticity.
- It mitigates neuronal damage in the CA1 region and reduces TNF-α and CXCL1 levels in the hippocampus and cerebrospinal fluid.
- Co-administration of r-TNF-α blocks wogonin's effects, while the TNF-α inhibitor etanercept replicates them.
- The study suggests wogonin's potential as an antidepressant through modulation of neuroinflammatory pathways.